Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Prime Medicine Inc.

Prime Medicine, Inc. ( ($PRME) ) has released its Q3 earnings. Here is a breakdown of the information Prime Medicine, Inc. presented to its investo...

Current Quarter	$-0.26	Next Quarter	$-0.27
Current Year	$-1.29	Next Year	$-0.95
QoQ Growth	-3.8%	YoY Growth	+26.4%
3Y EPS CAGR	+37.3%	Target Price	$6.28
Consensus	Buy	Upside	+73.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRME	$3.63	-1.63%	2.75M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRME	$3.63	-1.6%	2.75M
3
4
5
6

PRME

PRME

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Prime Medicine Inc. Data in Excel

Get Prime Medicine Inc. Data in Excel